Latest / This Week In Medicine
Circulation:January 6, 2026 Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial
The CAVIAR trial investigated whether adding the drug alirocumab to standard statin therapy could prevent artery disease in heart transplant recipients, a common cause of post-transplant mortality. While the study confirmed that this combination drastically lowered "bad" cholesterol levels without causing safety concerns, it failed to show a significant clinical benefit regarding physical heart health. Specifically, researchers discovered that the volume of arterial plaque continued to increase regardless of whether patients received the additional medication or a placebo. Ultimately…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.